

Corangil : angina pectoris.

Contributors

Allied Laboratories Ltd

Publication/Creation

London : Allied Laboratories Ltd.

Persistent URL

<https://wellcomecollection.org/works/w3545vy8>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

Corangil

ANGINA PECTORIS

DOSAGE Normal dosage is one tablet four times daily taken before meals. It is recommended that the last dose be taken 15 minutes before retiring.

In severe cases, a daily dosage of up to 8 tablets may be required. Although any number of tablets may be used sublingually, not more than eight cores should be swallowed daily.

Dosage may be reduced, according to response, to a maintenance level of 2—3 tablets per day.

SIDE EFFECTS Headache and dizziness associated with the use of glyceryl trinitrate. These effects are minimised when normal maintenance level is achieved.

PACKINGS Bottles of 50, 250, 1000.

PRICE Basic N.H.S. 3/7 for 25 tablets.

Cohen classification:— Category S.



ALLIED LABORATORIES LTD
140 PARK LANE · LONDON W.1

Corangil

ANGINA PECTORIS

FORMULA



Glyceryl Trinitrate 0.5 mg.
(Sublingual)

Diprophylline 120 mg.
Papaverine HCl. 60 mg.
Pentaerythrityl Tetranitrate 20 mg.
(Swallowed)

INDICATIONS

Prevention and treatment of angina pectoris.
Promotion of increased coronary flow following myocardial infarction.

CONTRA-INDICATIONS

Cerebral haemorrhage, acute coronary thrombosis.
(Administer with caution to patients with incipient glaucoma).

METHOD OF ADMINISTRATION

In both the acute attack and for maintenance, the tablet should remain beneath the tongue for 2 minutes before swallowing.

In Corangil, the unique presentation of glyceryl trinitrate in the soluble surface coating serves two purposes:

1. Producing immediate coronary vasodilatation with relief from pain where this is present.
2. Establishing an initial vasodilatation which enables the longer-acting drugs in the core to exert their vasodilatory and antispasmodic action more readily and more easily, providing both positive and prolonged relief from angina pectoris.



ALLIED LABORATORIES LTD

140 PARK LANE • LONDON W.1